Stratton J A, Mannel R S, Rettenmaier M A, Berman M L, DiSaia P J
University of California at Irvine, Medical Center, Orange 92668.
Gynecol Oncol. 1989 Jan;32(1):55-9. doi: 10.1016/0090-8258(89)90850-0.
The tumors from 38 patients with advanced or recurrent endometrial carcinoma were assayed by the subrenal capsule xenograft assay (SRCA) for sensitivity to hormonal and cytotoxic chemotherapy. Three patients initially received radiation therapy. All other patients received maximal surgical debulking followed by treatment with radiation therapy (5), and/or hormonal (19), and cytotoxic (30) chemotherapy. All the patients who received hormonal chemotherapy had progression of disease. There were 2 complete responses, 5 partial responses, and 26 disease progressions with cytotoxic chemotherapy; and 2 complete responses, 2 partial responses, and 5 disease progressions with radiation therapy. The SRCA was 100% predictive of the response of the tumors to hormonal therapy and had 75% sensitivity, 65% specificity, and 66% efficiency of the response of the tumors to cytotoxic chemotherapy. Laboratory assays of tumor response to radiation therapy were not measured. Those patients with early stage, well-differentiated tumors with no residual disease had the longest survival times. Absence of residual disease after the first surgery was the most important delineator of survival for all categories of patients.
对38例晚期或复发性子宫内膜癌患者的肿瘤进行了肾包膜下异种移植试验（SRCA），以检测其对激素和细胞毒性化疗的敏感性。3例患者最初接受了放射治疗。所有其他患者均接受了最大程度的手术减瘤，随后接受放射治疗（5例），和/或激素治疗（19例）以及细胞毒性化疗（30例）。所有接受激素化疗的患者病情均进展。细胞毒性化疗有2例完全缓解、5例部分缓解和26例病情进展；放射治疗有2例完全缓解、2例部分缓解和5例病情进展。SRCA对肿瘤对激素治疗的反应预测率为100%，对肿瘤对细胞毒性化疗反应的敏感性为75%、特异性为65%、有效率为66%。未检测肿瘤对放射治疗反应的实验室分析。那些处于早期、肿瘤分化良好且无残留疾病的患者生存时间最长。首次手术后无残留疾病是所有类别患者生存的最重要指标。
